Analyst BTIG upgraded Medtronic to a Buy rating and raised its price target to $100, citing strong Q1 FY2027 revenue of $9.76 billion driven by broad demand. The company is investing over $700 million in Heart Tech and Robotics, signaling a focus on innovation and durable growth. Medtronic also offers a dividend yield above 3%, nearing Dividend King status with 50 years of consecutive dividend increases, attracting long-term investors. This positive outlook supports confidence in Medtronic's leadership in healthcare technology and its financial growth potential.
Rising U.S. Treasury yields, with the 10-year surpassing 4.8%, are pressuring equities, especially growth stocks, amid concerns over fiscal deficits and potential rate hikes. Analysts expect immediate government intervention to contain long-term yiel...
Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...
Medtronic announced a 13.7% increase in revenue to $9.8 billion for Q1 of fiscal year 2027, driven by strong growth across cardiovascular, neuroscience, and medical surgical segments. The company raised its full-year organic revenue growth guidance t...
Medtronic has made a strategic investment of up to $80 million in Pi-Cardia, a company specializing in leaflet modification technologies for structural heart disease. This investment supports Medtronic's goal to enhance its structural heart portfolio...
Despite two major recessions in the past two decades, four healthcare companies—Johnson & Johnson, Abbott Laboratories, Medtronic, and Becton Dickinson—consistently raised their dividends each quarter. Their strong cash flows and inelastic demand for...
